Trastuzumab and pertuzumab plus carboplatin-based neoadjuvant therapy for HER2-positive breast cancer: a prospective cohort study with integrated genomic and transcriptomic biomarker analysis
Xiaoyan Qian, Xi Chen, Min Xiao, Lei Ji, Qiao Li, Jiayu Wang, Ying Fan, Yang Luo, Ruigang Cai, Bo Lan, Shanshan Chen, Fei Ma, Binghe Xu, Pin Zhang · 2025
Read Trastuzumab and pertuzumab plus carboplatin-based neoadjuvant therapy for HER2-positive breast cancer: a prospective cohort study with integrated genomic and transcriptomic biomarker analysis by Xiaoyan Qian, Xi Chen, Min Xiao, Lei Ji, Qiao Li, Jiayu Wang, Ying Fan, Yang Luo, Ruigang Cai, Bo Lan, Shanshan Chen, Fei Ma, Binghe Xu, Pin Zhang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12719586.txt.
Description
Qian and a large team tested in twenty twenty-five a paired-drug plan with chemo for breast cancer that bears a growth switch. The plan is the norm first care for that cancer kind. Data and marks for it in Chinese patients were thin, so they ran a group watch.
More than two hundred fifty patients were tracked through the care. Just past half had a full clear of tumor at surgery, a top mark of cure. Rates were higher when a kin hormone switch was off and with one chemo pick. Gene reads tied some marks to high or low clear rates. That may help pick who gains most.
Catalog record
| CREATOR | Xiaoyan Qian, Xi Chen, Min Xiao, Lei Ji, Qiao Li, Jiayu Wang, Ying Fan, Yang Luo, Ruigang Cai, Bo Lan, Shanshan Chen, Fei Ma, Binghe Xu, Pin Zhang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |